Liquidia initiated with a Perform at Oppenheimer

Oppenheimer analyst Andreas Argyrides initiated coverage of Liquidia with a Perform rating and no price price target. Despite receiving tentative approval in November 2021, Liquidia’s lead product candidate for the treatment of pulmonary arterial hypertension and pulmonary hypertension with interstitial lung disease – YUTREPIA – has yet to cross the regulatory finish line, the analyst tells investors in a research note. Liquidia is bogged down by ongoing and “what feels like endless litigation” with United Therapeutics (UTHR) as YUTREPIA continues to face commercial uncertainty as to when it might come to market, the firm added.